Pharming Group Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Fabrice Chouraqui
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 3.9yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
There's No Escaping Pharming Group N.V.'s (AMS:PHARM) Muted Revenues Despite A 29% Share Price Rise
May 10
Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 21Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price
Feb 14Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Nov 11Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 23Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Jun 20Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Mar 16Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price
Feb 17We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease
Dec 08Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Aug 05Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next
Mar 21These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat
Mar 19CEO
Fabrice Chouraqui
less than a year
Tenure
Mr. Fabrice Chouraqui, Ph D., PharmD, had been Chief Executive Officer of Cellarity, Inc. since May 2020 and serves as its President and Director. He has been Chief Executive Officer and Executive Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Strategic Advisor | less than a year | US$2.25m | 1.4% € 8.3m | |
| CEO & Executive Director | less than a year | no data | no data | |
| Chief Financial Officer | 4.5yrs | no data | 0.13% € 769.9k | |
| Chief Operations Officer | 5.8yrs | no data | 0.14% € 832.1k | |
| Investor Relations Manager | no data | no data | no data | |
| Chief Ethics & Compliance Officer | 4yrs | no data | 0.075% € 447.3k | |
| Chief People Officer | less than a year | no data | 0.0092% € 54.9k | |
| Chief Medical Officer | 3.9yrs | no data | 0.11% € 635.7k | |
| Chief Commercial Officer & GM Americas | 8.3yrs | no data | 0.077% € 456.9k | |
| Chief Business Officer | 1.7yrs | no data | 0.017% € 100.8k | |
| Consultant | 3.9yrs | no data | no data |
3.9yrs
Average Tenure
58yo
Average Age
Experienced Management: PHARM's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 4yrs | US$104.00k | 0.018% € 105.5k | |
| Independent Non-Executive Director | 4.4yrs | US$95.00k | 0.021% € 127.1k | |
| Independent Non-Executive Vice-Chairperson | 6yrs | US$96.00k | 0.024% € 140.7k | |
| Independent Non-Executive Director | 4yrs | US$101.00k | 0.018% € 105.5k | |
| Independent Non-Executive Director | 4.4yrs | US$109.00k | 0.021% € 127.1k | |
| Non-Executive Chairman of Board | 1.7yrs | US$154.00k | 0.0092% € 54.7k | |
| Independent Non-Executive Director | 4yrs | US$109.00k | 0.018% € 105.5k |
4.0yrs
Average Tenure
62yo
Average Age
Experienced Board: PHARM's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 23:54 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharming Group N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Savin | Edison Investment Research |
| Simon Scholes | First Berlin Equity Research GmbH |
| Joseph Pantginis | H.C. Wainwright & Co. |